|Bid||0.0700 x 0|
|Ask||0.0750 x 0|
|Day's Range||0.0750 - 0.0750|
|52 Week Range||0.0450 - 0.1200|
|Beta (3Y Monthly)||4.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce that it is undertaking a non-brokered private placement of $400,000. The warrant contains an acceleration clause such that if the Company’s shares trade at or more than $0.20 for a period of 10 days, the warrant holders may receive a 30 day notice accelerating the expiry date. The Company will pay finders fees to qualified finders of 10% cash and 10% broker warrants.
Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce the appointment of a new director and implementation of its succession plan for Voyageur’s CEO role. Effective July 1st, 2019, after four years of dedicated service, Mr. John Rucci has resigned his CEO and director positions. Mr. Rucci was instrumental in advancing projects in the Voyageur portfolio and Voyageur thanks him for his efforts with moving the Company forward.
Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing of the first tranche of $240,651.52 (3,210,687 units) of its non-brokered private placement (“Private Placement”) announced on April 25, 2019. After this issue, the Company will have 57,183,806 shares issued and outstanding. Charles Littlejohn, a director of the Company, purchased 990,021 units under the first tranche and his participation is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101").
CALGARY, Alberta, March 06, 2019 -- Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) updates the progress on plans to produce a barium contrast product through.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (VM.V) (the "Company") is pleased to announce that it intends to extend the expiry date of 6,304,210 outstanding share purchase warrants ("Warrants") that are exercisable for common shares of the Company at $0.18 and $0.20. The Warrants currently expire on March 2, 2019 and the Company intends to extend the expiry date to March 2, 2020.
The news release makes several references to “ore.” The term “ore” is a restricted term only to be used when referencing mineral reserves. No mineral reserves have been delineated on the Company’s properties or are supported by a pre-feasibility or feasibility study. The disclosure states that the Company has made a decision to proceed to production without first establishing mineral reserves. Companion Policy 43-101CP, 4.2(6) – Production Decision, requires specific disclosure addressing the risks associated with proceeding to production without first establishing mineral reserves. This disclosure is not provided in the news release.
Voyageur Minerals Ltd. (VM.V) (the “Company” or “Voyageur”) is pleased to announce that it has sent barite ore for testing to SGS Canada Inc. and to Allgaier Process Technology Inc. (“Allgaier”). A successful test using Allgaier’s density separator would enable Voyageur to gravity separate barite from the ore using air.
Voyageur Minerals Ltd. (VM.V) (the “Company” or “Voyageur”) is pleased to announce that it has applied for its bulk sample permit from the British Columbia Ministry of Mines. The 10,000 tonne bulk sample will be used for a major part of Voyageur’s feasibility study. The barite recovered from the bulk sample will be allocated to Voyageur’s barium contrast suspension manufacturing joint venture company, ImagingX Pharmaceuticals Inc. (“ImagingX”).
The company, named ImagingX Pharmaceuticals Inc. (“ImagingX”), is owned by Voyageur and Chief Medical Supply Ltd (“Chief”) as to 50% each. 2,000,000 grams of USP Barium Sulfate has been sourced from third party sources to be used for initial product formulation and near term sales.
Xnergy is a FINRA registered investment banking firm providing financing and merger, acquisition and disposition services to emerging growth and middle market companies. Xnergy services both public and private companies seeking debt and equity capital to fund growth initiatives, acquisitions, buyouts, and shareholder liquidly.
Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce that it has signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta. The joint venture will engage in the development, marketing and commercialization of human and animal radiographic contrast agents and related pharmaceutical products, focusing on development of barium sulfate contrast products.
Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing of $188,412 private placement consisting of 2,512,166 equity units. After this issue, the Company will have 53,975,119 shares issued and outstanding. Proceeds will be used for general working capital and to further the Company’s work program on its barite properties.